查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
非何杰金氏淋巴瘤市场：KOL洞察
市场调查报告书
商品编码
1773135

非何杰金氏淋巴瘤市场：KOL洞察

KOL Insight - Non-Hodgkin Lymphoma
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2个工作天内

价格
简介目录

本报告深入探讨了非何杰金氏淋巴瘤（NHL）标靶治疗的持续发展，并对目前和未来的治疗途径提供了详细的见解。报告探讨了主要上市药物类别的疗效和安全性比较，包括嵌合抗原受体T细胞疗法、双特异性抗体、抗体-药物偶联物、单株抗体和BTK抑制剂。报告中还探讨了新型疗法在中后期临床开发中的潜在影响，并重点介绍了可能影响未来处方趋势的关键临床试验。本报告探讨了未来几年非何杰金氏淋巴瘤治疗模式的变化，并重点介绍了非何杰金氏淋巴瘤面临的挑战和机会。

关键问题

  • 1.CAR-T 细胞疗法目前是许多地区治疗瀰漫大B细胞淋巴瘤（DLBCL）、滤泡性淋巴瘤（FL）和套细胞淋巴瘤（MCL）的主要手段，但在可预见的未来，其应用前景将如何发展？
  • 2.Roche和AbbVie/Genmab（以及欧洲的再生元）的T 细胞结合双特异性抗体现已获准用于治疗滤泡性淋巴瘤（FL），KOL 预计治疗方案将如何发展？
  • 3.Roche的Columvi 现已在欧洲获准（基于 STARGLO），且多项双特异性抗体在二线 DLBCL 治疗中的临床试验进行中，这种疗法能否成为标准治疗方案？
  • 4.再生元的双特异性抗体 Ordospono 如何被非何杰金氏淋巴瘤专家接受？
  • 5.KOL 对Merck公司用于治疗瀰漫性大B细胞淋巴瘤（DLBCL）的抗 ROR1 抗体偶联药物 zilovertamab vedotin 有何期待？
  • 6.AstraZeneca的Calquence 最近获得 FDA 和 EMA 的批准延期，可将其添加到套细胞淋巴瘤（MCL）的一线治疗中，而BeiGene的Brukinsa 参与 MANGROVE 临床试验。专家如何评估 BTK 抑制剂在这类第一线治疗的前景？
  • 7.B 细胞非何杰金氏淋巴瘤的治疗未来将如何发展？

主要品牌

  • Yescarta (axicabtagene ciloleucel)
  • Kymriah (tisagenlecleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Polivy (polatuzumab vedotin)
  • Zynlonta (loncastuximab tesirine)
  • Monjuvi/Minjuvi (tafasitamab)
  • Lunsumio (mosunetuzumab)
  • Epkinly/Tepkinly (epcoritamab)
  • Columvi (glofitamab)
  • Ordspono (odronextamab)
  • Brukinsa (zanubrutinib)
  • Calquence (acalabrutinib)
  • Imbruvica (ibrutinib)
  • Jaypirca (pirtobrutinib)
  • nemtabrutinib (MK-1026)
  • AZD0486 (TNB-486)
  • Adcetris (brentuximab vedotin)
  • zilovertamab vedotin (MK-2140)
  • golcadomide
  • sonrotoclax

部分参与专家名单

  • 美国莱文癌症研究所淋巴瘤主任
  • 美国莎拉‧坎农研究中心血液学研究主任
  • 美国迈阿密大学血液学教授兼淋巴瘤负责人
  • 英国牛津大学医院NHS基金会淋巴系统恶性肿瘤专科血液科顾问医生
  • 法国古斯塔夫鲁西研究所医学主任兼肿瘤血液科资深执业医师
  • 法国克莱蒙奥弗涅大学CHU Estaing血液学与细胞疗法教授

方法论

治疗趋势报告是透过对全球领先的KOL（关键意见领袖）的深入访谈彙编而成。致力于为关键疾病领域的当前和未来治疗格局提供领导者视角。关键意见领袖（KOL）的甄选是基于严格的筛选标准，包括全球声誉、临床专业知识以及在治疗领域的影响力。每次访谈都附有精心设计的讨论指南。这些指南由与关键意见领袖合作制定，并由行业专家进行同行评审，以确保所提问题全面且与当前市场动态相关。会在每份报告发布后持续进行12个月的市场监测，并及时提供来自关键意见领袖关于重要新闻事件、市场变化和市场发展的最新消息。

报告有何特别之处？

FirstWord Reports 是值得信赖的行业领导者，致力于製药业，为生物製药专业人士和决策者提供详细且可操作的洞察。深厚的行业知识使能够提供相关且有价值的洞察，帮助掌握新兴趋势并有效解决复杂挑战。凭藉广泛的研究以及来自领先专家和关键意见领袖的独立、公正的见解，报告能够提供所需的准确性和可靠性。独家获取其他地方无法获得的采访和资料，以及持续的市场监测，确保全面了解市场动态。报告涵盖 40 多个活跃疾病领域，汇集医生情报（包括 KOL 洞察和定量医生调查），以及行业专家对医疗事务、数位医疗、销售与市场营销、市场准入及其他领域问题的看法，助做出更明智的资料驱动决策，在快速变化的行业中保持竞争力。

简介目录

This comprehensive report delves into the evolving landscape of targeted therapies for Non-Hodgkin Lymphoma (NHL), providing you with in-depth insights into current and future treatment pathways. It explores the comparative efficacy and safety profiles of key marketed drug classes, including CAR T-cell therapies, bispecific antibodies, antibody-drug conjugates, monoclonal antibodies, and BTK inhibitors. The report also examines the potential impact of novel therapies in mid-to-late stage clinical development and highlights significant ongoing clinical trials that could shape future prescribing trends. This report offers a nuanced understanding of how treatment paradigms for NHL are likely to evolve over the next few years, identifying both challenges and opportunities in the field.

Key Questions Answered:

  • 1. CAR T-cell therapies are now a mainstay in DLBCL, FL and MCL in many localities, but how is their use expected to evolve in the foreseeable future?
  • 2. With T-cell-engaging bispecific antibodies from Roche and AbbVie/Genmab (and also Regeneron in Europe) now approved for FL, how do KOLs expect the treatment algorithm to evolve?
  • 3. With Roche's Columvi now approved in Europe (based on STARGLO), and several other trials of bispecifics in second-line DLBCL underway, could this modality become a standard of care in this setting?
  • 4. How is Regeneron's bispecific antibody Ordspono perceived by NHL specialists, and could it still find a role in an increasingly competitive market despite its relatively late entry?
  • 5. What are KOL expectations for Merck & Co.'s pipeline anti-ROR1 antibody-drug conjugate zilovertamab vedotin in the treatment of DLBCL?
  • 6. With the recent FDA and EMA extended approval for AstraZeneca's Calquence to include first-line MCL and the MANGROVE trial of BeiGene's Brukinsa underway, how do the experts weigh up the prospects for BTK inhibitors in this frontline setting?
  • 7. How might the treatment landscape for B-cell NHL evolve in the coming years?

Key Brands:

  • Yescarta (axicabtagene ciloleucel)
  • Kymriah (tisagenlecleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Polivy (polatuzumab vedotin)
  • Zynlonta (loncastuximab tesirine)
  • Monjuvi/Minjuvi (tafasitamab)
  • Lunsumio (mosunetuzumab)
  • Epkinly/Tepkinly (epcoritamab)
  • Columvi (glofitamab)
  • Ordspono (odronextamab)
  • Brukinsa (zanubrutinib)
  • Calquence (acalabrutinib)
  • Imbruvica (ibrutinib)
  • Jaypirca (pirtobrutinib)
  • nemtabrutinib (MK-1026)
  • AZD0486 (TNB-486)
  • Adcetris (brentuximab vedotin)
  • zilovertamab vedotin (MK-2140)
  • golcadomide
  • sonrotoclax

Partial List of Participating Experts:

  • Director, Lymphoma Division, Levine Cancer Institute, USA
  • Medical Director of Hematology Research, Sarah Cannon Research, USA
  • Professor of Medicine and Chief of Lymphoma Section at Division of Hematology, University of Miami, USA
  • Consultant Haematologist specialising in lymphoid malignancies, Oxford University Hospitals NHS Foundation Trust, UK
  • Medical Director and Senior Practitioner in onco-hematology, Gustave Roussy Institute, France
  • Professor, Service d'Hematologie et de Therapie Cellulaire, CHU Estaing, Universite Clermont Auvergne, France

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.